The mTOR/NF-κB Pathway Mediates Neuroinflammation and Synaptic Plasticity in Diabetic Encephalopathy

Diabetic encephalopathy, a severe complication of diabetes mellitus, is characterized by neuroinflammation and aberrant synaptogenesis in the hippocampus leading to cognitive decline. Mammalian target of rapamycin (mTOR) is associated with cognition impairment. Nuclear factor-kappa B (NF-kappa B) is a transcription factor of proinflammatory cytokines. Although mTOR has been ever implicated in processes occurring in neuroinflammation, the role of this enzyme on NF-kappa B signaling pathway remains unclear in diabetic encephalopathy. In the present study, we investigated whether mTOR regulates the NF-kappa B signaling pathway to modulate inflammatory cytokines and synaptic plasticity in hippocampal neurons. In vitro model was constructed in mouse HT-22 hippocampal neuronal cells exposed to high glucose. With the inhibition of mTOR or NF-kappa B by either chemical inhibitor or short-hairpin RNA (shRNA)-expressing lentivirus-vector, we examined the effects of mTOR/NF-kappa B signaling on proinflammatory cytokines and synaptic proteins. The diabetic mouse model induced by a high-fat diet combined with streptozotocin injection was administrated with rapamycin (mTOR inhibitor) and PDTC (NF-kappa B inhibitor), respectively. High glucose significantly increased mTOR phosphorylation in HT-22 cells. While inhibiting mTOR by rapamycin or shmTOR significantly suppressed high glucose-induced activation of NF-kappa B and its regulators IKK beta and I kappa B alpha, suggesting mTOR is the upstream regulator of NF-kappa B. Furthermore, inhibiting NF-kappa B by PDTC and shNF-kappa B decreased proinflammatory cytokines expression (IL-6, IL-1 beta, and TNF-alpha) and increased brain-derived neurotrophic factor (BDNF) and synaptic proteins (synaptophysin and PSD-95) in HT-22 cells under high glucose conditions. Besides, the mTOR and NF-kappa B inhibitors improved cognitive decline in diabetic mice. The inhibition of mTOR and NF-kappa B suppressed mTOR/NF-kappa B signaling pathway, increased synaptic proteins, and improved ultrastructural synaptic plasticity in the hippocampus of diabetic mice. Activating mTOR/NF-kappa B signaling pathway regulates the pathogenesis of diabetic encephalopathy, such as neuroinflammation, synaptic proteins loss, and synaptic ultrastructure impairment. The findings provide the implication that mTOR/NF-kappa B is potential new drug targets to treat diabetic encephalopathy.

Automated summary

Diabetic encephalopathy, characterized by neuroinflammation and aberrant synaptogenesis, involves the mTOR and NF-kappa B signaling pathways. Inhibiting mTOR and NF-kappa B can reduce inflammatory cytokines expression and increase synaptic proteins, leading to the improvement of cognitive decline in diabetic models. This study suggests that targeting the mTOR/NF-kappa B pathway could be a potential therapeutic strategy for treating diabetic encephalopathy and related cognitive impairments.